科瑞产品

- 客户定制产品 - 前列腺素系列 - PI3K Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - mTOR Inhibitors - c-Met Inhibitors - DNA/RNA Inhibitors - HER2 Inhibitors - Raf Inhibitors - JAK Inhibitors - Others - SRC Inhibitors - AKT Inhibitors - CDK Inhibitors

浙江省台州市椒江开发大道东段288号万达广场2号楼

0576-88813233

0576-88670057

sales@crene.cn

合作客户/Partner

当前位置：科瑞产品

Telavancin

规格	价格	库存	数量
在线咨询大包装询价加入购物车

如您需要更多数量的报价，请点击立即获取报价或者通过电子邮件sales@crene.cn把您需要的数量信息提交给我们我们会在第一时间回复您，谢谢！

产品信息

产品名称：Telavancin	纯度：98% min
CAS NO：372151-71-8	溶解度：Soluble in DMSO
分子式：C₈₀H₁₀₆Cl₂N₁₁O₂₇P	包装：可按客户要求包装
分子量：1755.63	贮存：-20℃

质量控制

备注说明

Telavancin a semisynthetic lipoglycopeptide vancomycin-derivative and antimicrobial agent developed by Theravance for overcoming resistant Gram-positive bacterial infections, specifically methicillin-resistant Staphylococcus aureus (MRSA).

参考文献

1: Schroeder CP, Van Anglen LJ, Dretler RH, Adams JS, Prokesch RC, Luu Q, Krinsky AH. Outpatient treatment of osteomyelitis with telavancin. Int J Antimicrob Agents. 2017 Jul;50(1):93-96. doi: 10.1016/j.ijantimicag.2017.01.034. Epub 2017 Apr 26. PubMed PMID: 28456704.

2: Das B, Sarkar C, Das D, Gupta A, Kalra A, Sahni S. Telavancin: a novel semisynthetic lipoglycopeptide agent to counter the challenge of resistant Gram-positive pathogens. Ther Adv Infect Dis. 2017 Mar;4(2):49-73. doi: 10.1177/2049936117690501. Epub 2017 Mar 8. Review. Erratum in: Ther Adv Infect Dis. 2017 Nov;4(6):193. PubMed PMID: 28634536; PubMed Central PMCID: PMC5467880.